Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | DRD4 | P21917 | 6/20 | 0.55 |
| ▸ | DRD3 | P35462 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15923398 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL7621648 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL2802924 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL20530530 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL7432568 | 0.98 | DRD2 (0.57) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL6626845 | 0.91 | DRD2 (0.59) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL16418450 | 0.91 | GAA (0.51) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL3977735 | 0.89 | DRD2 (0.46) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL3977737 | 0.89 | DRD2 (0.46) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL14095592 | 0.89 | PRMT1 (0.54) | DRD3GAAL3MBTL1KCNH2PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368194-B | Method for producing (meth) acryloyl group-terminated polyisobutylene polymer | 株式会社钟化 | 2021-03-19 | — | — | CN | disclosed |
| US-10604598-B2 | Method of producing (meth)acryloyl-terminated polyisobutylene polymer | KANEKA CORPORATION (JP) | 2020-03-31 | — | — | US | disclosed |
| WO-2019066306-A1 | COMPOUND, COATING COMPOSITION COMPRISING SAME, ORGANIC LIGHT EMITTING DEVICE USING SAME, AND MANUFACTURING METHOD THEREOF | 주식회사 엘지화학 | 2019-04-04 | — | — | WO | disclosed |
| US-20180362676-A1 | METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER | KANEKA CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3388454-A1 | METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER | Kaneka Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| EP-2498746-B1 | SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES | UNILEVER PLC NO 41424 (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-8309064-B2 | Skin care compositions comprising phenoxyalkyl amines | CONOPCO, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| CN-102686212-A | Skin care compositions comprising phenoxyalkyl amines | UNILEVER PLC | 2012-09-19 | — | — | CN | disclosed |
| CN-101880340-B | Load type metallocene catalyst as well as preparation method and application thereof | SHANGHAI RES INST CHEMICAL IND | 2012-06-20 | — | — | CN | disclosed |
| US-20110245429-A1 | Cross Linked Organic Conductive Layer | GOUGH, NEIL (GB) | 2011-10-06 | — | — | US | disclosed |
| US-20110110870-A1 | SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES | CONOPCO, INC., D/B/A UNILEVER (US) | 2011-05-12 | — | — | US | disclosed |
| CN-101880340-A | Load type metallocene catalyst as well as preparation method and application thereof | SHANGHAI INST OF CHEMICAL INDUSTRY | 2010-11-10 | — | — | CN | disclosed |
| US-5661169-A | HAVE AFFINITY FOR VASOPRESSIN AND/OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1997-08-26 | — | — | US | disclosed |
| EP-0694536-A1 | 1-Benzyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245429-A1 | Cross Linked Organic Conductive Layer | GJB2, GJA1, KCNH3 | DRD2 1779/4885DRD4 1007/4885DRD3 1820/4885 |
| US-20110110870-A1 | SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES | CUTA, TYR, FLNA | DRD2 1366/4885DRD4 2141/4885DRD3 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.